Ukoniq (umbralisib) / TG Therap 
Welcome,         Profile    Billing    Logout  
 7 Diseases   4 Trials   4 Trials   1090 News 


«1234567891011»
  • ||||||||||  Revlimid (lenalidomide) / BMS
    [VIRTUAL] Follicular Lymphoma with Focus on Therapy (MEETING ROOM A) -  May 14, 2021 - Abstract #ICLLM2021ICLLM_37;    
    Based on the results of phase II and observationalstudies, high-dose chemotherapy with ASCT may prolong PFSand OS and should be considered, especially in young patientswho experience a very short remission after anti-CD20 antibodycontaining chemotherapy regimens. These studies and data onbispecific antibodies, CAR-T-cells and allo transplantation willbe discussed further by Professor Koen van Besien.
  • ||||||||||  Zarzio (filgrastim biosimilar) / Novartis
    [VIRTUAL] EX VIVO DRUG SENSITIVITY IDENTIFIES COMBINATION TREATMENT WITH PI3K/BCL-2 INHIBITORS FOR MONOTHERAPY-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA () -  May 13, 2021 - Abstract #EHA2021EHA_1228;    
    Background The phosphatidylinositol 3-kinase inhibitors (PI3Ki) idelalisib and duvelisib are approved for relapsed chronic lymphocytic leukemia (CLL)...However, treatment with the p110d-selective PI3Ki umbralisib plus venetoclax showed more selective targeting of CLL cells compared to normal B cell and T cells than combinations involving a pan-PI3Ki...Drug sensitivity assessment of an ibrutinib (BTK inhibitor), idelalisib and venetoclax refractory CLL patient indicated combination of idelalisib and venetoclax as a promising therapeutic option...Interestingly, the patient continued to show a strong ex vivo response to the pan-PI3K inhibitors buparlisib, copanlisib and pictilisib, suggesting that these therapies may be considered for CLL patients who relapse on currently available targeted therapies...This demonstrates that ex vivo drug sensitivity assessments can guide clinical decisions in CLL. We further showed that CLL cells from refractory patients remain sensitive to pan-PI3Ki ex vivo, suggesting pan-PI3Ki as potential treatment options to be explored for relapsing CLL patients.
  • ||||||||||  Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap, Calquence (acalabrutinib) / AstraZeneca
    Enrollment open, Trial initiation date:  Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL (clinicaltrials.gov) -  May 10, 2021   
    P2,  N=60, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2021 --> Dec 2020
  • ||||||||||  Ukoniq (umbralisib) / TG Therap
    Journal:  PI3Kδ-CK1ε Inhibitor Umbralisib Shows Promise in R/R Indolent NHL. (Pubmed Central) -  Mar 21, 2021   
    In an indirect treatment comparison accounting for differences in cross-trial characteristics, umbralisib demonstrated significantly lower AE discontinuations (~3 times lower), favorable DoR, and a lower AE management cost burden (>2 times lower) than currently approved PI3Kis for R/R FL patients. Umbralisib showed efficacy and in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL).
  • ||||||||||  Jakafi (ruxolitinib) / Incyte, Ukoniq (umbralisib) / TG Therap
    Trial completion date, Trial primary completion date:  TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea (clinicaltrials.gov) -  Mar 12, 2021   
    P1,  N=60, Active, not recruiting, 
    Umbralisib showed efficacy and in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL). Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  Ukoniq (umbralisib) / TG Therap
    Review, Journal:  Targeting Casein Kinase 1 (CK1) in Hematological Cancers. (Pubmed Central) -  Mar 5, 2021   
    While no selective CK1 inhibitors have reached clinical stage to date, one dual PI3Kδ and CK1ε inhibitor, umbralisib, is currently in clinical trials for CLL and NHL patients. In MDS, AML and MM, inhibition of CK1α, acting via activation of p53 pathway, showed promising preclinical activities and the first CK1α inhibitor has now entered the clinical trials.